Navigation Links
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
Date:5/5/2009

ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to replace one or more of the current first-line antitubercular drugs and simplify patient therapy, was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows superior antibacterial activity against drug sensitive and both multi-drug resistant and extensively-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The Phase 1B study will assess safety, pharmacokinetics and tolerability of multiple ascending doses of SQ109 in three cohorts of healthy volunteers.

"We are pleased to begin this Phase 1B safety trial and to continue the clinical development of SQ109, a potentially valuable new drug candidate for the treatment of both uncomplicated and drug resistant TB," said Dr. Carol Nacy, Sequella CEO. "With the growing number of new TB cases within HIV-infected populations, there is no time to waste. Clinicians and patients alike are desperate for new drugs to shorten treatment times and improve patient outcomes. In a global world, the safety assessment of a new drug candidate with the antitubercular properties of SQ109 is an important milestone for patients on every continent, including North America."

The SQ109 Phase 1B trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), through a contract awarded to Dynport Corporation. The investigative site is the Quintiles Phase 1 facility in Overland Park, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializin
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Psylin Neurosciences Commences Development of Compound for Depression
5. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 OncoTAb, Inc., a ... company, announced that Pinku Mukherjee, Ph.D. has received the ... of Governors’ highest faculty honor. Mukherjee received the award, ... for her innovative research and development of cancer diagnostics ... a crowning moment in my scientific career,” said Mukherjee, ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... world market for antithrombotic drugs will reach $22.4bn in ... Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 ... purpose of that investigation is to provide forecasts and ... a business information publisher and consultancy in ...
(Date:5/1/2015)... and RESEARCH TRIANGLE PARK, N.C. , May ... announced today that Roger Jeffs , Ph.D., President and ... and update on the company,s business at the Deutsche Bank ... Boston, Massachusetts . The presentation will take ... Time, and can be accessed via a live webcast on ...
(Date:4/30/2015)... CA (PRWEB) April 30, 2015 Cytokinetics, Incorporated ... first quarter of 2015 were $4.4 million, compared to $8.0 ... loss for the first quarter was $8.9 million, or $0.23 ... net loss for the same period in 2014, of $8.7 ... of March 31, 2015, cash, cash equivalents and investments totaled ...
Breaking Biology Technology:OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8
... 12 Bayer CropScience announced,today that its vegetable ... Paragon Seed Inc. Based in Salinas, California, Paragon ... lettuce varieties. The,company with sales of US-Dollar 8.5 ... market leaders in the United States in this ...
... RAMON, Calif., Dec. 12 Odyssey Thera, Inc.,announced ... Office granted,U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation,Assays ... ADME, cancer,biology, immunology, infectious disease and gene therapy." ... PCA process., The patent describes a method ...
... N.M., Dec. 12 Biomoda, Inc. (OTC,Bulletin Board: ... New,Mexico Institute of Mining and Technology (New Mexico ... to collaborate on clinical,studies and the development of ... commercialization of its assay for the early,detection of ...
Cached Biology Technology:Bayer CropScience's Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed 2Bayer CropScience's Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed 3Odyssey Thera Granted U.S. Patent for Animal Imaging 2Biomoda Announces Collaborative Agreement With New Mexico Tech 2
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... stink bug, was discovered in the western hemisphere in 2008 ... at the Port of Long Beach. Since then it has ... Utah, southern and west-central New Mexico, and western Texas. ... Journal of Integrated Pest Managment called " ...
... This news release is available in ... of labor is more efficient than a struggle through life without ... from Research Group Experimental Ecology and Evolution at the Max Planck ... University in Jena, Germany came to this conclusion when they performed ...
... shows that reforesting the Lower Mississippi Alluvial Valley can ... of sediment entering the area,s rivers and streamsand ultimately ... recently published the results of the study by ... Leininger, and Matt Moran. The Lower Mississippi Alluvial ...
Cached Biology News:Division of labor in the test tube 2Division of labor in the test tube 3Study shows reforestation in Lower Mississippi Valley reduces sediment 2
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
... Proteins ,Contains sufficient components to prepare ... gel analysis , ,Includes:, , Mem-PER ... , (contains sufficient reagents for extracting 25 ... of 10 mg each) Kit , ...
... The Amplifluor UniPrimer-fluorescein is a ... energy transfer pair (fluorescein and non-fluorescent ... tail. The UniPrimer is identical ... Amplifluor Universal Detection System (S7901) and ...
...
Biology Products: